Lineage Cell Therapeutics Stock Fundamentals
| BTX Stock | ILS 194.00 3.40 1.78% |
Lineage Cell Therapeutics fundamentals help investors to digest information that contributes to Lineage Cell's financial success or failures. It also enables traders to predict the movement of Lineage Stock. The fundamental analysis module provides a way to measure Lineage Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lineage Cell stock.
Lineage |
Lineage Cell Therapeutics Company Gross Profit Analysis
Lineage Cell's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Lineage Cell Gross Profit | 4.69 M |
Most of Lineage Cell's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lineage Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Lineage Cell Therapeutics reported 4.69 M of gross profit. This is 99.79% lower than that of the Healthcare sector and 99.51% lower than that of the Biotechnology industry. The gross profit for all Israel stocks is 99.98% higher than that of the company.
Lineage Cell Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lineage Cell's current stock value. Our valuation model uses many indicators to compare Lineage Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lineage Cell competition to find correlations between indicators driving Lineage Cell's intrinsic value. More Info.Lineage Cell Therapeutics is number one stock in price to book category among its peers. It also is number one stock in price to sales category among its peers fabricating about 34.33 of Price To Sales per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lineage Cell by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lineage Cell's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Lineage Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lineage Cell's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics of similar companies.Lineage Cell is currently under evaluation in gross profit category among its peers.
Lineage Fundamentals
| Price To Book | 1.14 X | |||
| Price To Sales | 39.20 X | |||
| Revenue | 4.99 M | |||
| Gross Profit | 4.69 M | |||
| EBITDA | (37.2 M) | |||
| Net Income | (45.99 M) | |||
| Cash And Equivalents | 27.1 M | |||
| Cash Per Share | 0.18 X | |||
| Total Debt | 5.09 M | |||
| Debt To Equity | 3.10 % | |||
| Current Ratio | 3.51 X | |||
| Book Value Per Share | 1.09 X | |||
| Cash Flow From Operations | (30.88 M) | |||
| Number Of Employees | 76 | |||
| Beta | 2.87 | |||
| Market Capitalization | 512.15 M | |||
| Total Asset | 101.66 M | |||
| Z Score | 60.0 | |||
| Net Asset | 101.66 M |
About Lineage Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.